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Background: Spontaneous intracerebral hemorrhage is a disease with high morbidity, high disability rate, high
mortality, and high economic burden. Whether patients can benefit from surgical evacuation of hematomas is still
controversial, especially for those with moderate-volume hematomas in the basal ganglia. This study is designed to
compare the efficacy of endoscopic surgery and conservative treatment for the moderate-volume hematoma in
spontaneous basal ganglia hemorrhage.
Methods: Patients meet the criteria will be randomized into the endoscopic surgery group (endoscopic surgery for
hematoma evacuation and the best medical treatment) or the conservative treatment group (the best medical
treatment). Patients will be followed up at 1, 3, and 6 months after initial treatment. The primary outcomes include
the Extended Glasgow Outcome Scale and the Modified Rankin Scale. The secondary outcomes consist of the
National Institutes of Health Stroke Scale and the mortality. The Barthel Index(BI) will also be evaluated. The sample
size is 100 patients.
Discussion: The ECMOH trial is a randomized controlled trial designed to evaluate if endoscopic surgery is better
than conservative treatment for patients with moderate-volume hematomas in the basal ganglia.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TRC-11001614
(http://www.chictr.org/en/proj/show.aspx?proj=1618)
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hemorrhageBackground
Spontaneous intracerebral hemorrhage (SICH) is a dis-
ease with high morbidity, high disability rate, high mor-
tality, and high economic burden [1,2]. Its annual
incidence is about 20 cases per 100,000 population [3,4].
More than 70% patients end up with death or depend-
ence [5,6].
The main clinical management of SICH includes surgi-
cal and medical treatment. Whether patients can benefit
from surgery is still controversial, especially for those
with basal ganglia hemorrhage, which is the major* Correspondence: neuroswch@gmail.com
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reproduction in any medium, provided the orsubtype of SICH [7]. Surgical evacuation of hematomas
can relieve the mass effect and reduce the harmful sub-
stance released during their coagulation, liquefaction,
and resolution [8-10], but surgical procedures may also
injure the brain tissue, and cause other operative com-
plications. These disadvantages reduce the benefit of sur-
gery. Some clinical trials were carried out to compare
surgery with medical treatment. The most famous trial
is the STICH trial conducted by Mendelow et al. [5].
1033 patients were randomized. After 6 months follow-
up, 26% of patients in the early surgery group had a
favourable outcome compared with 24% in the group of
initial conservative treatment. Early surgery did not
show significant advantages. However, in this study less
than 25% of the operations were minimally invasive.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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also carried out [11-13]. But none of the trials and sys-
tematic reviews provide sufficient evidence for the
choice of treatments [6,14-16].
In clinical practice, neurologists and neurosurgeons tend
to choose conservative treatment for patients with small-
volume hematomas, and surgery for those with large-
volume hematomas [17]. However, when the volume of
the hematoma exceeds 60 ml, neither of the methods give
much help [18]. Treatments for moderate-volume hemato-
mas have the most uncertainty. Some recently randomized
trials indicate these patients may benefit from minimally
invasive surgery [13,19]. Kim et al. [19] randomized 387
patients with basal ganglia or thalamus hematomas to
stereotactic-guided evacuation (group A) or conservative
treatment (group B), and the mean hematoma volume was
23.1 ml. At the end of 6 months follow-up, the mean
score of modified Barthel index was 90.9 in group A and
62.4 in group B, and the mean score of modified Rankin
scale was 1.2 in group A and 3.0 in group B. Patients
received stereotactic-guided evacuation had better clinical
outcomes and motor function.
Endoscopic surgery is one of the minimally invasive
ways for hematoma evacuation. Compared with other
surgical methods, it has advantages as follows. A). The
hematoma evacuation is performed under direct vision
of neurosurgeons. It’s much easier to spot any bleeding
site, so that the risk of postoperative rebleeding is lower.
B). The evacuation rate of hematomas is higher because
of a wider vision. C). This also leads to less brain retrac-
tion and brain tissue injury. D). The operation time is
shorter. Cho et al. [20] carried out a randomized con-
trolled trial which compared endoscopic surgery, stereo-
tactic aspiration and craniotomy. The results showed
endoscopic surgery had the highest hematoma evacu-
ation rate, the lowest mortality and complication rate,
and shorter waiting time than stereotactic aspiration.
However, there are few randomized controlled trials
which contrast endoscopic surgery and conservative
treatment. The trial completed by Auer et al. [21] in
1989, showed 28% lower of the mortality in the endo-
scopic surgery group than the medical treatment group
after 6 months follow-up. But this trial did not restrict
the volume of hematomas.
It's not clear whether endoscopic surgery gives this
type of patients better outcomes, so we have designed




To compare the efficacy of endoscopic surgery and con-
servative treatment for the moderate-volume hematoma
in spontaneous basal ganglia hemorrhage.Inclusion criteria
 Spontaneous basal ganglia hemorrhage confirmed by
computed tomography(CT).
 The volume of the hematoma is between 20 ml to
40 ml. Small intraventricular hemorrhage is not
counted.
 Admission within 36 hours from the ictus.
 Age between 15 to 75 years old.
 Glasgow Coma Score(GCS) ≥ 8.
Exclusion criteria
 Any sign of brain herniation, including deep coma,
unilateral or bilateral pupil dilation, abnormal
posture, or unstable vital signs.
 Hemorrhage caused by aneurysm, vascular
malformations, tumor apoplexy, trauma, or cerebral
infarction. Computed tomography angiography will
be performed.
 Large intraventricular hematomas which occupy half
of the cross section area of the lateral ventricle on
CT scans, or hydrocephalus caused by hematocele.
 Primary intraventricular hemorrhage.
 Dysfunction of blood coagulation,
thrombocytopenia, or history of taking any kind of
drugs which affect coagulation function in the past
40 days.
 Before the ictus, the patient has severe physical or
mental illness which causes significant disability, or
the patient has other severe comorbidity.
 The patient is pregnant.
Sample size
The rate of the favourable outcome of patients with
basal ganglia hemorrhage is about 30% for conservative
treatment [5,6] and 60% for endoscopic surgery [22-24].
A sample size of 86 will be required with a significance
level of 5% (2-sided) and a power of 80%. In consider-
ation of the loss to follow-up, the sample size is enlarged
to 100.
Randomization
The minimization method is adopted for the patients
allocation, and it’s performed by a minimization soft-
ware. When the qualification of a patient is confirmed,
the investigator sends the basic information of the
patient to a special trialist who is responsible for patients
randomization. After the information of the patient is
imported, the software will randomize him/her into the
endoscopic surgery group or the conservative treatment
group. The presetted variables for minimization are age,
hematoma volume, and admission GCS.
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patients' condition deteriorates during conservative treat-
ment, and the surgical indications are clear, hematoma
evacuation will be performed after fully informed consent.
Blinding
Both patients and surgeons cannot be blinded. In order
to minimize the measurement bias, the following proce-
dures are made. A). Patient outcomes will be measured
by two special investigators who are not involved in the
allocation and the treatment. Before the outcome meas-
urement starts, patients, their relatives, and the related
medial staff will be told not to reveal any information
about the treatment. B). Every patient will have a gauze
covered on the hemorrhage side of the head to conceal
the scar or baldness. C). Because the follow-up forms
and the treatment forms are printed on the same set of
Case Report Form (CRF), these two investigators must
hand in a copy of the original score sheets to the Quality
Monitoring Board (QMB), before they are allowed to get
the CRF of the patient. D). The statistical analysis will be
made by a statistician who doesn't participate in the im-
plementation of the trial, and the treatment information
of the groups will be blinded.
Measurement of the hematoma volume
The ABCs method is adopted to measure the hematoma
volume: Volume(ml) = (A×B×C)/2[25]. “A” is the long
axis of the hematoma on the CT slice where the
hematoma has the largest area. “B” is the longest axis of
the hematoma perpendicular to the long axis on the
same CT slice. “C” is the product of the interslice dis-
tance and the count of slices on which the hematoma is
visible. The intraventricular hematoma is not counted.
The rebleeding or hematoma expansion is defined as a
10 ml increase between two CT scans.
Treatments
Endoscopic surgery group
This group of patients will receive endoscopic surgery
and the best medical treatment. The surgery will be per-
formed as soon as possible after the randomization, and
the medical treatment will be started immediately. Neu-
rosurgeons will decide surgical approaches according to
the location, size, and shape of hematomas. The hemato-
mas will be evacuated as much as possible with the help
of the angled endoscope, but the stiffly attached clot
won’t be removed by force in order to prevent unneces-
sary damage, and the restricted intracavity operation will
be the principle during the hematoma evacuation.
A “Rebleeding test” will be performed after the
hemostasis. For patients with hypertension, the blood
pressure will be slowly elevated to the level before
the anesthesia, and for other patients, a raise of20~ 30 mmHg will be gained. The anesthetist will main-
tain this level of blood pressure for 10 minutes. Only if
there is no new bleeding site, neurosurgeons can start
to close.
Conservative treatment group
The best medical treatment will be provided to this
group of patients right after the admission. A “multistep
blood pressure control” will be carried out. The range of
the first reduction is limited to 20% of the admission
level for patients with hypertension, and it should be
accomplished in half an hour. If the patients' systolic
blood pressure exceeds 225 mmHg, the goal is lower
than 180 mmHg. The level of blood pressure will be
maintained for 8 hours and gradually reach the normal
standard in 72 hours.
After patients are stabilized, the rehabilitation will be
started as early as possible.
Follow-up
Patients will be followed up at 1, 3, and 6 months after
initial treatment.
Outcome assessment
Both investigators have been trained at least 20 hours by
multimedia, bedside practice, and a qualification exam,
before they start to evaluate patient outcomes.
Primary outcomes
The primary outcomes of the study are the Extended
Glasgow Outcome Scale (GOSE)[26] and the Modified
Rankin Scale (mRS) at 6 months after initial treatment.
Both scales will be measured with structured interviews.
Secondary outcomes
The secondary outcomes include the National Institutes
of Health Stroke Scale(NIHSS) and the mortality after
6 months since initial treatment.
Other outcome
The Barthel Index (BI) will also be evaluated.
Ethics
This study is conducted in accordance with the Declar-
ation of Helsinki and guideline for Good Clinical Prac-
tice. All patients and their relatives are fully informed
about the trial, and they have had a copy of the informed
consent form. The trial is approved by the Biological
and Medical Ethics Committee (BMEC) of West China
Hospital (2011Reviewed-No.92).
Data collection and management
The allocation data of patients is kept by the trialist who
specializes in randomization. Neurosurgeons should fill
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pleted by another two investigators trained for outcome
assessment. Double input will be used in the data entry.
The QMB and the principal investigator will check and
examine the data, then the database will be locked and
sent to a statistician.
Adverse and severe adverse events
Adverse event (AE) is any undesirable incident happen-
ing to patients during the study. It will be recorded on
CRF, including a description of the event, the correlation
with the trial, the starting date, the ending date, actions
taken and their efficacy, and the patient outcome. Severe
adverse event (SAE) is defined as the event of death or
vegetative state. Severe disability is not included, because
basal ganglia hemorrhage tends to cause severe disabil-
ity. SAE will also be recorded on CRF. All AEs and SAEs
will be reported to the QMB and the BMEC, and the
time limit for SAE report is 24 hours.
Statistical analysis
Both Intention To Treat (ITT) and Per-Protocol (PP)
analysis will be performed. The level of significance is
0.05, and Power is 80%. The quantitative data will be
analyzed by t-test. Chi-square test will be used to analyze
the categorical data. For the ordinal data, Wilcoxon rank
test is adopted. And survival analysis will be carried out
for further comparison of mortality. Logistic regression
will be used to adjust the effect of multivariables.
Discussion
Spontaneous basal ganglia hemorrhage is very likely to
cause death, independence, disability, and lead to a great
financial burden, so it’s always a hot issue in neurology
and neurosurgery. There are already more than 10 ran-
domized controlled trials referring to the treatment
choices of SICH, but we still designed this study due to
the following reasons. A). To evacuate or not, it’s con-
troversial, especially for moderate-volume hematomas.
B). It’s reasonable to evacuate the hematoma considering
its mechanical, chemical, and biological harm to the
brain tissue [8-10]. C). As a minimally invasive tech-
nique, endoscopic surgery may reveal the benefit of the
hematoma evacuation, which is probably covered by the
secondary injury caused by traditional craniotomy. D).
There is a lack of randomized controlled trial focusing
on endoscopic surgery for the moderate-volume
hematoma in spontaneous basal ganglia hemorrhage.
For patients in the conservative treatment group, if
their condition deteriorates because of hematoma
expansion or rebleeding during the trial, and the surgical
indications are clear, then hematoma evacuation should
be performed. The crossover will be analyzed in both
ways: ITT and PP.Surgical approaches for the hematoma evacuation in
the basal ganglia include the temporal approach, the
frontal approach, and the transsylvian approach. The last
one is often performed under the microscope, so it won’t
be applied in this study. The temporal approach usually
provides the shortest distance from the cortex to the
hematoma, but it may cause injury to the visual pathway,
and if the hematoma is elliptical, neurosurgeons may fail
to evacuate the frontal part of the hematoma because of
the blind angle. In the frontal approach, the trajectory of
endoscope is parallel to the long axis of the hematoma,
so neurosurgeons get a better view through this
approach, and it’s advised to be used for hematomas lar-
ger than 50 ml [27]. However, for small and moderate
volume hematomas, much further distance is needed to
reach them by the frontal approach, which means more
brain tissue damage. Also, the aspect ratio of moderate-
volume hematomas is more approximate to 1:1 than the
large ones, which makes fewer blind angle through the
temporal approach. In this study, surgical approaches
will be decided according to the location, size, and shape
of hematomas.
In conclusion, the ECMOH trial is a randomized con-
trolled trial designed to assess if endoscopic surgery is
better than conservative treatment for patients with
moderate-volume hematomas in the basal ganglia.
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